CN116323676A - 抗Claudin18.2和CD3的双特异性抗体以及其用途 - Google Patents

抗Claudin18.2和CD3的双特异性抗体以及其用途 Download PDF

Info

Publication number
CN116323676A
CN116323676A CN202180066494.1A CN202180066494A CN116323676A CN 116323676 A CN116323676 A CN 116323676A CN 202180066494 A CN202180066494 A CN 202180066494A CN 116323676 A CN116323676 A CN 116323676A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
antibody
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180066494.1A
Other languages
English (en)
Chinese (zh)
Inventor
周帅祥
管哲
伍伟伟
高亚荣
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovent Biologics Suzhou Co Ltd
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of CN116323676A publication Critical patent/CN116323676A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180066494.1A 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途 Pending CN116323676A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020110544286 2020-09-29
CN202011054428 2020-09-29
PCT/CN2021/121286 WO2022068810A1 (zh) 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途

Publications (1)

Publication Number Publication Date
CN116323676A true CN116323676A (zh) 2023-06-23

Family

ID=80949663

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180066494.1A Pending CN116323676A (zh) 2020-09-29 2021-09-28 抗Claudin18.2和CD3的双特异性抗体以及其用途

Country Status (9)

Country Link
US (1) US20230357389A1 (https=)
EP (1) EP4223778A4 (https=)
JP (1) JP2023544143A (https=)
KR (1) KR20230079165A (https=)
CN (1) CN116323676A (https=)
AU (1) AU2021352532B2 (https=)
CA (1) CA3200865A1 (https=)
TW (1) TWI837517B (https=)
WO (1) WO2022068810A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240167685A (ko) * 2022-03-28 2024-11-27 포트비타 바이오로직스 (싱가포르) 피티이. 리미티드 항-Claudin18.2 및 CD3 이중특이성 항체를 포함하는 제제 및 이의 제조 방법과 용도
CN117229398A (zh) * 2022-06-15 2023-12-15 中山康方生物医药有限公司 抗cldn18.2抗体、其药物组合物及用途
KR20240101987A (ko) * 2022-12-23 2024-07-03 주식회사 와이바이오로직스 클라우딘-18.2에 특이적으로 결합하는 단클론항체 및 이의 용도
CN116813782B (zh) * 2023-08-10 2024-01-23 北京百普赛斯生物科技股份有限公司 一种Claudin-18.2特异性抗体及其应用
WO2025162454A1 (zh) * 2024-02-02 2025-08-07 北京昌平实验室 双特异性抗体和细胞因子融合蛋白及其应用
CN120829517A (zh) * 2024-04-22 2025-10-24 鲁南新时代生物技术有限公司 抗cldn18.2/cd3双特异性抗体及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2920209A1 (en) * 2012-11-13 2015-09-23 BioNTech AG Agents for treatment of claudin expressing cancer diseases
CN105073776A (zh) * 2012-11-13 2015-11-18 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
CN110023336A (zh) * 2016-09-23 2019-07-16 生物技术公司 用于治疗表达密蛋白之癌症疾病的与密蛋白6或密蛋白18.2和cd3结合的双特异性三价抗体
US20200055932A1 (en) * 2018-08-03 2020-02-20 Amgen Research (Munich) Gmbh Antibody Constructs for CLDN18.2 and CD3

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
CN104968367B (zh) * 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
WO2014075697A1 (en) * 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
CN106589127A (zh) * 2015-10-16 2017-04-26 钜川生物医药 一种pcsk9抗体及其制备方法和应用
EP3577137A1 (en) * 2017-02-02 2019-12-11 Merck Patent GmbH Preferred pairing of antibody domains
SG11201907422RA (en) * 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
EP3409322A1 (en) * 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
EP3694885A1 (en) * 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
US12404512B2 (en) * 2018-05-01 2025-09-02 Ambrx, Inc. Method for optimizing antibody expression
WO2019242505A1 (zh) * 2018-06-17 2019-12-26 上海健信生物医药科技有限公司 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2920209A1 (en) * 2012-11-13 2015-09-23 BioNTech AG Agents for treatment of claudin expressing cancer diseases
CN105073776A (zh) * 2012-11-13 2015-11-18 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
CN110023336A (zh) * 2016-09-23 2019-07-16 生物技术公司 用于治疗表达密蛋白之癌症疾病的与密蛋白6或密蛋白18.2和cd3结合的双特异性三价抗体
US20200055932A1 (en) * 2018-08-03 2020-02-20 Amgen Research (Munich) Gmbh Antibody Constructs for CLDN18.2 and CD3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GUOYUN ZHU等: "Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer", SCIENTIFIC REPORTS, vol. 9, 10 June 2019 (2019-06-10) *

Also Published As

Publication number Publication date
EP4223778A4 (en) 2024-11-06
KR20230079165A (ko) 2023-06-05
AU2021352532B2 (en) 2026-01-15
AU2021352532A1 (en) 2023-05-25
US20230357389A1 (en) 2023-11-09
JP2023544143A (ja) 2023-10-20
AU2021352532A9 (en) 2025-03-13
EP4223778A1 (en) 2023-08-09
TW202216783A (zh) 2022-05-01
TWI837517B (zh) 2024-04-01
WO2022068810A1 (zh) 2022-04-07
CA3200865A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
TWI809426B (zh) 抗Ｃｌａｕｄｉｎ１８.２抗體以及其用途
TWI793395B (zh) 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體
CN116261590B (zh) 抗cd3抗体以及其用途
TWI837517B (zh) 抗claudin 18.2和cd3的雙特異性抗體以及其用途
WO2020156439A1 (zh) 抗cd79b抗体、其抗原结合片段及其医药用途
CN112166125A (zh) 全人源的抗lag-3抗体及其应用
IL323270A (en) Antibody against PTK7 and its uses
CN113366020B (zh) 抗pd-l1的新型抗体及其用途
CN120603856A (zh) 三特异性抗原结合分子及其应用
WO2021175191A1 (zh) 抗tim-3抗体及其用途
HK40083793A (en) Anti-claudin18.2 antibody and use thereof
CN120659811A (zh) 双特异性抗原结合分子及其应用
CN120818052A (zh) 抗il-15抗体以及其用途
CN120329439A (zh) 一种单克隆抗体及其应用
WO2022105751A1 (zh) TGFβRII融合蛋白以及其用途
HK40059424A (en) Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination